AG
ITCI

Algert Global’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Algert Global’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,701
Closed -$7.88M – 1378
2025
Q1 		$7.88M Buy
59,701
+34,840
+140% +$4.34M 0.19% 142
2024
Q4 		$2.08M Sell
24,861
-20,489
-45% -$1.68M 0.05% 595
2024
Q3 		$3.32M Sell
45,350
-20,990
-32% -$1.58M 0.09% 398
2024
Q2 		$4.54M Sell
66,340
-64,271
-49% -$4.46M 0.15% 202
2024
Q1 		$9.04M Buy
130,611
+51,001
+64% +$3.51M 0.35% 45
2023
Q4 		$5.7M Buy
79,610
+4,260
+6% +$245K 0.23% 110
2023
Q3 		$3.92M Sell
75,350
-14,124
-16% -$823K 0.18% 170
2023
Q2 		$5.67M Buy
+89,474
New +$5.58M 0.25% 91
2022
Q3 		– Sell
-4,301
Closed -$246K – 1363
2022
Q2 		$246K Buy
+4,301
New +$244K 0.02% 967

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Algert Global's ITCI Position: Q2 2025 in Review

Algert Global sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 59,701 shares — an estimated $7.88M sold.

Algert Global first reported a position in ITCI in Q2 2022 and held it in 9 quarters. The position peaked at $9.04M in Q1 2024. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Algert Global reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 59,701 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $7.88M.
  • Algert Global first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 9 quarters.
  • Algert Global's Intra-Cellular Therapies Inc. position peaked at $9.04M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.